

Mayumi Sugita

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1682144/publications.pdf>

Version: 2024-02-01

14
papers

768
citations

1040056

9
h-index

1199594

12
g-index

14
all docs

14
docs citations

14
times ranked

1673
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | Chemotherapy-Resistant Human Acute Myeloid Leukemia Cells Are Not Enriched for Leukemic Stem Cells but Require Oxidative Metabolism. <i>Cancer Discovery</i> , 2017, 7, 716-735. | 9.4 | 582 |
| 2 | Hematopoietic cytokines mediate resistance to targeted therapy in FLT3-ITD acute myeloid leukemia. <i>Blood Advances</i> , 2019, 3, 1061-1072. | 5.2 | 42 |
| 3 | Allogeneic TCR $\alpha\beta$ deficient CAR T-cells targeting CD123 in acute myeloid leukemia. <i>Nature Communications</i> , 2022, 13, 2227. | 12.8 | 25 |
| 4 | Targeting the epichaperome as an effective precision medicine approach in a novel PML-SYK fusion acute myeloid leukemia. <i>Npj Precision Oncology</i> , 2021, 5, 44. | 5.4 | 20 |
| 5 | CD123 as a Therapeutic Target Against Malignant Stem Cells. <i>Hematology/Oncology Clinics of North America</i> , 2020, 34, 553-564. | 2.2 | 18 |
| 6 | BCL6 maintains survival and self-renewal of primary human acute myeloid leukemia cells. <i>Blood</i> , 2021, 137, 812-825. | 1.4 | 18 |
| 7 | Allogeneic Tcr $\alpha\beta$ Deficient CAR T-Cells Targeting CD123 Prolong Overall Survival of AML Patient-Derived Xenografts. <i>Blood</i> , 2016, 128, 765-765. | 1.4 | 16 |
| 8 | Targeting CD123 in blastic plasmacytoid dendritic cell neoplasm using allogeneic anti-CD123 CAR T cells. <i>Nature Communications</i> , 2022, 13, 2228. | 12.8 | 14 |
| 9 | Selection and characterization of antibody clones are critical for accurate flow cytometry-based monitoring of CD123 in acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2018, 59, 978-982. | 1.3 | 11 |
| 10 | Applicability and reproducibility of acute myeloid leukaemia stem cell assessment in a multi-centre setting. <i>British Journal of Haematology</i> , 2020, 190, 891-900. | 2.5 | 11 |
| 11 | Chemical probes and methods for single-cell detection and quantification of epichaperomes in hematologic malignancies. <i>Methods in Enzymology</i> , 2020, 639, 289-311. | 1.0 | 9 |
| 12 | In Vivo Response to Cytarabine Chemotherapy Uncovers the Role of the Oxidative and Energetic Metabolism in the Chemoresistance of Human Primary AML Stem Cells. <i>Blood</i> , 2015, 126, 4269-4269. | 1.4 | 2 |
| 13 | Efficacy Proof of Concept for Allogeneic CD123 Targeting CAR T-Cells Against Primary Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Efficient Control of Tumor Progression in PDX Model and Potential Loss of CD123 Expression in Relapsed Disease. <i>Blood</i> , 2019, 134, 2659-2659. | 1.4 | 0 |
| 14 | Methods to monitor in vivo expansion and efficacy of CAR-T cells in preclinical models. <i>Methods in Cell Biology</i> , 2022, 167, 185-201. | 1.1 | 0 |